STAT+: New results show Cassava’s Alzheimer’s drug has placebo-like efficacy

Newly released data should erase any investor’s hope that twin Phase 3 studies of simufilam, an experimental Alzheimer's drug from Cassava Sciences, will prove successful.

Cassava Sciences had long claimed that its experimental treatment for Alzheimer’s disease was capable of improving the cognition of patients — a benefit no other Alzheimer’s drug has ever shown.

But mid-stage study results updated on Tuesday now show the cognitive status of patients worsening to the point where Cassava’s drug, called simufilam, doesn’t look any more effective than a placebo.

Continue to STAT+ to read the full story…